3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
47
Neoplasms
5
Neoplasm Metastasis
5
Metastatic Castration-Resistant Prostate Cancer
3
Adenocarcinoma
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasm, Residual
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Lymphoma, Follicular
1
Fatigue
1
Depression
1
Colorectal Neoplasms
1
Castration Resistant Metastatic Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Interventions
Specimen Handling
5
Biopsy
5
Whole-Body Irradiation
3
Mycophenolic Acid
3
Cyclosporine
3
Cyclophosphamide
3
Azacitidine
3
venetoclax
2
ruxolitinib
2
fludarabine phosphate
2
decitabine and cedazuridine drug combination
2
Sirolimus
2
Melphalan
2
Injections
2
Granulocyte Colony-Stimulating Factor
2
Decitabine
2
Busulfan
2
veliparib
1
tocilizumab
1
tagraxofusp
1
posaconazole
1
peginterferon alfa-2b
1
iadademstat
1
gilteritinib
1
fludarabine
1
fedratinib
1
axatilimab
1
Tranexamic Acid
1
Topotecan
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
enzalutamide
×
90 days
×
Clear all
No trials found.